Two Onc Docs Cervical Cancer 2025 UPDATE
12 snips
Jul 21, 2025 This discussion dives into the latest on cervical cancer, spotlighting prevention strategies and vaccination trends. They explore the critical role of HPV types 16 and 18 and highlight global disparities in screening. Management of localized cases is meticulously reviewed, featuring fertility-sparing options and radical surgery thresholds. The conversation also covers advances in treatment for locally advanced and metastatic stages, introducing new therapies and immunotherapy options. Tune in for essential insights and updates that could impact patient care.
AI Snips
Chapters
Transcript
Episode notes
HPV Is The Dominant But Not Sole Risk
- HPV types 16 and 18 cause about 70% of cervical cancers, but most HPV infections do not progress to cancer.
- HIV, immunosuppression, smoking, and prior high-grade CIN raise progression risk and warrant closer surveillance.
Vaccinate Early And Offer Catch-Up
- Start HPV vaccination discussions around ages 11–12 and complete the series before sexual activity whenever possible.
- Offer catch-up vaccination through age 26 and consider through age 45 on an individual basis.
Screen And Biopsy To Confirm Lesions
- Screen asymptomatic patients with Pap smears and perform colposcopy with biopsy for visible lesions.
- Use LEEP or cone biopsy when abnormal cells exist but no visible lesion is seen to obtain diagnostic tissue.